[1] Coghill D.The impact of medications on quality of life in Attention-Deficit Hyperactivity Disorder[J].CNS Drug,2010,24(10):843-866. [2] Coghill D,Danckaerts M,Sonuga-Barke E,et al.Practitioner review: quality of life in child mental health-conceptual challenges and practical choices[J].J Child Psychol Psychiatry,2009,50(5):544-561. [3] Moss MS,Hoffman CJ,Mossey J,et al.Changes over 4 years in health,quality of life,mental health,and valuation of life[J].J Aging Health,2007,19(6):1025-1044. [4] Danckaerts M,Sonuga-Barke EJ,Banaschewski T,et al.The quality of life of children with attention deficit/hyperactivity disorder: a systematic review[J].Eur Child Adolesc Psychiatry,2010,19(2):83-105. [5] Escobar R,Schacht A,Peter M.W,et al.Quality of life and attention-deficit/hyperactivity disorder core symptoms[J].Journal of Clinical Psychopharmacology,2010,30(2):145-151. [6] Leo B.Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants[J/OL].Psychiatric Quarterly 2011[2011-3-25]. [7] Flapper BC,Schoemaker MM.Effect of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD[J].Develop Med Child Neurol,2008,50(4):294-299. [8] Manos M,Frazier TW,Landgraf JM,et al.HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system[J].Curr Med Res Opin,2009,25(12):3001-10. [9] Rothenberger A,Becker A.An observational study of once-daily modified-release methylphenidate in ADHD:quality of life,satisfaction with treatment and adherence[J].Eur Child Adolesc psychiatry,2011,20(2):257-265. [10] Kordon A,Stollhoff K.Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH[J].Posgrod Med,2011,123(5):27-38. [11] Bukstein OG,Arnold LE,Landgraf JM,et al.Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life andmedication satisfaction for children with attention-deficit/hyperactivity disorder?[J].Child Adolesc Psychiatry Ment Health,2009,3(1):39. [12] Cheng JY,Chen RY,Ko JS,et al.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and metaregression analysis[J].Psychopharmacology (Berl),2007,194(2):197-209. [13] Prasad S,Harpin V,Poole L,et al.A multi-centre,randomised,open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)[J].Curr Med Res Opin,2007,23(2):379-394. [14] Escobar R,Montoya A,Polavieja P,et al.Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol,2009,19(3):253-263. [15] Saylor K,Williams DW,Schuh KJ,et al.Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD[J].Curr Med Res Opin,2010,26(9):2087-2095. [16] Peter MW,Schacht A,Dittmann RW,et al.Effect of atomoxetine on quality of life and family burden: results from a randomized,placebo-controlled,double-blind studyin children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder[J].Qual Life Res,2011,20(5):691-702. |